Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyv
NEW YORK, NY / ACCESS Newswire / January 25, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal se
RADNOR, Pa., Jan. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United S
Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
10:00am, Saturday, 25'th Jan 2025
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeut
NEW ORLEANS , Jan. 24, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 7, 2025 to file lead plaintiff applications in a securi
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal se
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal se
Robbins LLP is Investigating Allegations that Kyverna Therapeutics, Inc. (KYTX) Provided Investors with Misleading Information in Connection with its IPO
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching February 7, 2025, deadline to seek the role of lead plaintiff in a federal securit
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
02:15pm, Friday, 24'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal se
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or trac
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
01:00pm, Friday, 24'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the feder
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Su
